FDA Biologics (BLA & Biosimilars)Original article
Meeting 1: Patient and Care Partner Perspectives on Safety Considerations for Approved Gene Therapy Treatments for Rare Diseases - 09/20/2024
Neutral
AI Analysis
Summary
FDA CBER held a patient listening meeting on September 20, 2024 to gather patient and care partner perspectives on safety considerations for approved gene therapy treatments for rare diseases.
Importance:2/10
Sentiment:
0.00
gene therapyrare diseasesFDApatient listening meetingsafetyCBER
Read the original article
Published by FDA Biologics (BLA & Biosimilars) on September 10, 2026 2:29 PM